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Abstract 
 
Designing proteasome adaptors to deplete specific proteins from cells 
 
Kimberly Elizabeth Bowen, Ph.D. 
The University of Texas at Austin, 2019 
 
Supervisor:  Andreas Matouschek 
 
Cellular protein levels are governed by their rates of synthesis and degradation, 
and both processes are intricately regulated. One way to study the role of a protein in the 
cell is to artificially deplete it and observe the effects. The most common methodology 
for depleting proteins inhibits expression of the target through RNA interference. 
However, this technique acts at the protein synthesis level and cannot be used to study 
long-lived proteins or post-translational modifications. Thus, a complementary approach 
that acts on the proteins themselves would be useful. One method is to target a protein to 
the cell’s degradation machinery, the Ubiquitin Proteasome System (UPS). Proteins are 
targeted to the proteasome by the covalent attachment of ubiquitin molecules, which are 
recognized by the proteasome. The substrate is then translocated into the proteasome’s 
proteolytic core and degraded into short peptides, while the ubiquitin molecules are 
cleaved off and recycled. Recently, methods have been developed to deplete proteins by 
inducing their ubiquitination, which accelerates their degradation by the proteasome. 
Ubiquitin is a signaling molecule for numerous cellular pathways other than proteolysis, 
however, and inducing ubiquitination does not always lead to degradation. Therefore, I 
have developed a system to degrade specific proteins in cells using chimeric adaptors that 
 viii 
shuttle proteins directly to the proteasome without the need for ubiquitination. I have 
shown that this system can be successfully applied to several proteins in vitro and that the 
adaptors can induce degradation of model and endogenous proteins in cells. 
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Chapter 1: Introduction 
THE UBIQUITIN PROTEASOME SYSTEM 
Cellular protein concentrations are determined by their rates of synthesis and 
degradation. Most of the protein degradation in eukaryotic cells is controlled by the 
ubiquitin proteasome system (UPS). The UPS plays a central role in various cellular 
pathways, including cell cycle control, stress response, and signal transduction. At the 
center of the UPS is the proteasome complex, which is responsible for degrading 
hundreds of proteins in the cell, including misfolded and damaged proteins as well as 
regulatory proteins. Proteins are targeted to the proteasome by the covalent attachment of 
ubiquitin molecules, which are recognized by the proteasome. The substrate is then 
translocated into the proteasome’s proteolytic core and degraded into short peptides, 
while the ubiquitin molecules are cleaved off and recycled1. In this section I will describe 
the proteasome’s structure and targeting of proteins to the proteasome for degradation. 
For simplicity, I will use subunit names corresponding to the Saccharomyces cerevisiae 
proteasome. 
Structure of the 26S proteasome 
The proteasome is a ~2.5 megadalton macromolecular machine consisting of over 
30 subunits. It exists predominantly in the 26S form which contains a 20S core particle, 
where the proteolytic activity is located, and either one or two 19S regulatory particles, 
where target proteins bind and are translocated into the core (Figure 1)2,3. The 19S 
particle can be further divided structurally into two subcomplexes called the base and the 
lid (Figure 1). The base is located on top of the core particle and contains ubiquitin-
binding subunits as well as translocation machinery. The lid provides structural support 
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by wrapping around one side of the base and also contains the deubiquitinating enzyme 
(DUB) Rpn112. Many other proteins make transient interactions with the proteasome as 
well, including assembly chaperones4, non-stoichiometric DUBs5,6, and ubiquitin-like 
domain (UBL) proteins such as Rad237,8. 
When a protein is targeted for degradation, it is conjugated with a series of 
ubiquitin molecules which serve as a proteasome binding tag. The proteasome contains at 
least three receptors for ubiquitin: Rpn1, Rpn10, and Rpn132,9-11 (Figure 1). These 
receptors are located some distance apart from each other, potentially allowing for 
recognition of substrates with varying ubiquitin chain lengths and conformations2. Once a 
ubiquitinated protein binds to the proteasome, the protein is unfolded and translocated to 
the core through a narrow channel in the base, which contains a ring of six ATPases 
associated with various cellular activities (AAA+). In order to initiate translocation, the 
substrate protein must contain an unstructured region (or initiation region) where the 
AAA+ motor can engage the polypeptide with enough grip and force to unfold the 
substrate12,13. Interestingly, the sequence composition and amino acid properties of the 
initiation region affect whether a protein will be degraded. For example, biased amino 
acid sequences confer stability to a substrate14, while higher hydrophobicity and stiffness 
correlate with increased degradation efficiency12. Many regulatory proteins contain 
disordered regions, and mutating or deleting these regions greatly influences the proteins’ 
half-life15. 
Upon engagement, the base undergoes a dramatic conformational shift, which 
aligns the translocation channel above the core particle and positions the DUB Rpn11 
directly over the channel where it cleaves off the ubiquitin chain from the substrate2,16,17. 
As the substrate is unfolded, coordinated ATP hydrolysis drives conformational changes 
of the AAA+ motors, which contain pore loops that interact with the substrate and 
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mechanically “pull” the target through the channel3,18. The direct interactions between 
motors and the substrate could explain the proteasome’s sequence preferences, as the 
affinity of the base to the pore loops would affect their ability to translocate the 
substrate14.  
After translocation through the base, the substrate enters the 20S core particle 
through a narrow channel opening. Access to this opening, or gate, is tightly controlled 
such that it only opens upon RP binding and initiation of translocation19,20. This 
regulation helps prevent cleavage of functional proteins in the cell. The core consists of 
four heteroheptameric rings which form a barrel shape with a large channel in the center. 
Two of the rings are composed of homologous a subunits and they flank the central b 
subunit rings where the protease activity occurs (Figure 1). Three of the b subunits 
contain proteolytic active sites with trypsin-, chymotrypsin-, or caspase-like activities, 
which cleave the substrate protein into small peptides of approximately three to eight 
amino acids each21. The active sites in the core are positioned facing inwards so that only 
the unfolded substrate is degraded, further protecting folded cellular proteins22. 
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Figure 1: Structure of the 26S proteasome.  
Half of the S. cerevisiae 26S proteasome, with one 19S regulatory particle atop the two 
rings in the 20S core particle. In green are the three known stoichiometric ubiquitin 
receptors; in beige is the base, containing the AAA+ ATPases which translocate the 
substrate; cyan denotes the lid, with the DUB Rpn11 in red; in light and dark grey are the 
a and b rings of the core particle, respectively. PDB: 4CR2.  
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Targeting to the proteasome 
As mentioned earlier, proteins to be degraded are usually covalently tagged with 
one or more ubiquitin chains that bind to the proteasome. Ubiquitin is a small, ~8kDa 
protein that is highly evolutionarily conserved amongst eukaryotes, with only three amino 
acid differences between yeast and humans. Ubiquitin contains seven lysine residues 
where other ubiquitin molecules can be attached. Typically, a ubiquitin molecule is 
attached through its C-terminus to a lysine residue in the target protein, although in rare 
cases a cysteine residue or the N-terminus can serve as the starting point for the chain23-
26. The presence of multiple locations for attachment within ubiquitin enables a variety of 
mono- or polyubiquitin patterns and geometries to be formed, allowing for a diverse 
“code” that is interpreted by many different players in the cell. Indeed, ubiquitination 
signals are used in myriad cellular pathways, such as membrane trafficking, DNA 
damage repair, and transcriptional regulation in addition to proteasomal targeting27-31. 
How each linkage type affects the fate of a target remains elusive. All linkage 
types have been observed in cells, but their detailed function is still unclear32. The 
canonical proteasome degradation signal is a polyubiquitin chain attached through 
K4833,34. The minimum requirement for degradation is four K48-linked ubiquitins35. K11-
linked ubiquitin chains are associated with endoplasmic reticulum-associated degradation 
(ERAD), but usually exist in heterotypic chains, with other linkage types present, and do 
not lead to degradation in vitro as homotypic chains32,36. K63 chains are known to bind to 
the proteasome, but whether they lead to degradation is debated4,37. Met1-linked chains 
have been implicated in immune receptor signaling38. The roles of K6, K27, K29, and 
K33 chains are not fully understood39. 
Proteins are ubiquitinated through a cascade of enzymes that activate and 
covalently attach ubiquitin molecules onto the substrate. In most cases, three types of 
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enzymes are used: Enzyme 1 (E1), the ubiquitin-activating enzyme; E2, ubiquitin-
conjugating enzyme; and E3, the ubiquitin ligase enzyme. First an E1 enzyme activates 
ubiquitin by forming a thioester bond with the C-terminus of ubiquitin, which induces a 
conformational change in the E1 that allows for binding to an E2 conjugating enzyme. 
The ubiquitin is transferred to the E2 enzyme and then to the E3 ubiquitin ligase enzyme, 
which attaches the C-terminus of ubiquitin to a lysine residue on the substrate protein40-42. 
In general, the E2 enzyme defines which of the seven lysine residues to attach the next 
ubiquitin molecule to (linkage type), while the E3 confers specificity to the target 
substrate41,42. Occasionally, an additional enzyme E4 plays a role in ubiquitination at 
multiple sites on the target (multiubiquitination)43. 
In eukaryotes, there are only one or two E1 enzymes and tens of E2s, but there are 
hundreds of E3s that recognize a diverse array of substrate proteins44,45. E3 enzymes can 
be classified into two structurally distinct categories which contain either Really 
Interesting New Gene (RING) or homologous to the E6-AP carboxy terminus (HECT) 
domains. RING domain E3s bind both the substrate and the E2 enzyme, recruiting the E2 
into proximity with the substrate and allowing the transfer of ubiquitin directly from the 
E2 to the substrate44. HECT domain E3s are active players in the cascade, where the 
ubiquitin is transferred to the E3 active site and from there attached to the substrate46. 
Ubiquitin-independent and adaptor-mediated targeting to the proteasome 
While ubiquitin chains are the primary proteasome binding tags in the cell, 
ubiquitination of a protein is not required or sufficient in itself for degradation. Several 
studies have shown, that localization to the proteasome alone is sufficient for degradation 
both in vitro and in vivo13,47,48, as in the case of antizyme-mediated degradation of 
ornithine decarboxylase (ODC). When ODC binds to antizyme, its C-terminus is exposed 
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and is recognized directly by the 26S proteasome for degradation47,49. Antizyme also 
mediates the degradation of several other proteins, including nucleolar c-Myc, cyclin D1, 
and Aurora-A in a ubiquitin-independent manner50-52. In these cases, the proteasome 
recognizes the target directly, without the need for any proteasome-binding tag. 
In addition to direct proteasome interaction with the substrate, there are proteins 
that act as adaptors to localize substrates to the proteasome. One class of adaptor proteins 
called UBL-UBA proteins contains a ubiquitin-like (UBL) domain attached to one or 
more ubiquitin-associated (UBA) domains. UBL domains adopt a similar structural 
conformation to ubiquitin and are recognized by all three ubiquitin receptors in the 
proteasome53,54. In fact, a UBL-specific recognition site distinct from its ubiquitin 
binding site in Rpn1 has been mapped11,53,54.  
One UBL-UBA protein is yeast Rad23, which is involved in DNA damage repair 
and shuttling substrates to the proteasome55. Rad23 contains one UBL and two UBA 
domains that bind multiubiquitinated proteins56,57. In humans, there are two functionally 
somewhat distinct homologs of Rad23, called hHR23a and hHR23b (Rad23b). While the 
homologs are redundant in the DNA repair pathway58, only the Rad23b UBL binds 
efficiently to the proteasome59. Because Rad23 binds to the proteasome and 
simultaneously to ubiquitinated proteins, it is believed to act as a shuttle factor that can 
localize specific targets to the proteasome for degradation7. Rad23 itself escapes 
degradation and is thought to recycle and act catalytically as a proteasome adaptor60-62. 
CONTROLLING PROTEIN CONCENTRATION THROUGH TARGETED DEGRADATION 
The UPS controls the concentration of hundreds of cellular proteins, and it is 
possible to harness the proteasome’s power to artificially tune the amount of specific 
proteins. Being able to control a protein’s concentration in cells is useful for several 
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reasons. First, the most common methodology for studying protein function is by 
depleting the protein from cells to study the effects on relevant downstream 
pathways63,64. In addition, many diseases are caused or exacerbated by the overexpression 
of particular proteins65-68 or the expression of mutated proteins69-71. This is the basis of 
molecularly-targeted therapies, where the inhibition or depletion of a particular disease-
causing protein can treat or even cure patients. Therefore, development of novel 
technologies which alter protein concentration are always in demand. 
RNA interference (RNAi) is widely used to control protein expression levels by 
preventing the protein’s synthesis72. In this method, a short piece of RNA complementary 
(either completely for silencing RNA (siRNA) or with a few mismatches for microRNA 
(miRNA)) to the gene of interest is introduced into the cell, where it is processed to a 
single strand that binds the endogenous mRNA. This prevents translation by triggering 
degradation or sequestration of the mRNA or direct inhibition of the translational 
machinery73-75. In this way, synthesis of the protein is greatly reduced, so basic function 
of the protein can be inferred by changes in downstream pathways and new phenotypes76. 
RNAi has been used to screen for protein function as well as disease targets72,77-79. 
Advances in RNA delivery technology have also made RNAi an effective therapeutic 
agent, with one FDA-approved RNAi therapy and clinical trials underway for an array of 
diseases80,81. 
While RNA interference has been used successfully for studying protein function, 
it has several drawbacks as a research tool and therapeutic. For example, sequence 
similarities among different genes can lead to off-target base pairing, causing a miRNA-
like silencing effect82,83. This can lead to side effects, toxicity, and false positives. 
Decreasing protein levels by RNAi also depends on the target’s intrinsic degradation rate, 
making naturally long-lived proteins difficult to deplete with RNAi84. In addition, many 
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proteins are regulated through post-translational modifications (PTMs), which tune their 
activity, stability, and interaction network85. These effects cannot be studied via RNAi 
alone because it functions at the pre-translational level85. Therefore, complementary 
methods that act on the proteins themselves have been developed, such as targeting 
specific proteins to the UPS for degradation.  
PROTACS: Using small molecules to induce ubiquitination 
Several technologies have been introduced that decrease individual protein 
concentrations via the UPS. Protein-targeting chimeras (PROTACs) consist of a target-
binding domain (usually a small molecule) connected through a linker to an E3-binding 
motif (Figure 2a). PROTACs bring a protein of interest into proximity with the E3, 
leading to the protein’s ubiquitination and subsequent degradation86,87. Importantly, 
PROTAC-mediated degradation of the target protein is catalytic, meaning that one 
PROTAC molecule can lead to turnover of multiple proteins. Generally, the target-
binding and E3-binding domains are small molecules that bind to an interface on the 
target protein or ubiquitin ligase88. The most common E3-binding ligand recognizes Von 
Hippel Lindau (VHL), which is part of an E3 ligase complex that normally targets HIF1α 
for degradation89,90. Another widely-used E3 ligase binding molecule is thalidomide (and 
its derivatives), which interacts with Cereblon (CRBN), an adaptor for the Cullin 4a E3 
ligase complex91,92. A third ligand is ethyl bestatin, which binds to cellular inhibitor of 
apoptosis protein 1 (cIAP1), a protein that is overexpressed in certain cancers and 
contains an E3 ligase domain93,94. Finally, a PROTAC was recently developed that 
utilizes nutlin, a compound that binds the E3 ligase mouse double minute 2 (MDM2) and 
disrupts MDM2 binding to its natural substrate, p5395. The PROTAC created based on 
MDM2 actually serves double duty: it retains its ability to stabilize p53 and also induces  
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Figure 2: Induced ubiquitination and degradation of specific targets. 
A) A PROTAC consists of a target binding molecule (warhead, orange) connected 
through a linker to an E3-binding motif (pink). The PROTAC bridges the target and E3, 
leading to ubiquitination of the target protein, which is then released and degraded by the 
proteasome. B) An antibody that binds a specific target is introduced into a cell. The E3 
TRIM21 recognizes the antibody and autoubiquitinates. The whole complex is then 
degraded by the proteasome. 
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degradation of the target protein. Interestingly, changing just the E3 ligand (and therefore 
the recruited E3) can significantly affect degradation of a target protein. For example, a 
promiscuous kinase inhibitor that binds to many kinases degraded completely different 
sets of targets depending on whether it was attached to a VHL binder or a CRBN 
binder96. This is most likely due to the distinct structural conformations of the two E3s, 
which would affect the accessibility of the active site to the target96,97. 
PROTACs have been generated against a variety of target proteins classes, such 
as kinases, bromodomains, and hormone receptors94,98. Usually, the target-binding 
domain (also called warhead) is a previously-developed small molecule that recognizes 
the target protein with high affinity and specificity99. One PROTAC uses 4-
hydroxytamoxifen, a molecule whose tight interaction with the oncoprotein estrogen 
receptor α (ERα) is well-established93,100,101. If there are no available molecules that bind 
to the target, high-throughput screens followed by extensive optimization are required to 
develop a target-binding compound102,103. Even with a warhead that binds tightly and 
selectively, the extent of PROTAC-mediated target degradation rarely correlates with 
warhead binding affinity profiles96,104. In other words, a high-affinity warhead does not 
necessarily lead to better degradation than a lower-affinity one. In fact, just because a 
molecule binds to a protein on its own does not mean it will induce degradation of the 
target at all when attached to the rest of the PROTAC. One study found a promiscuous 
kinase inhibitor that binds to hundreds of kinases on its own degraded less than half of a 
verified subset of targets when in PROTAC form, even though the PROTAC retained 
target-binding ability96. Surprisingly, the PROTACs that induced the highest depletion 
were not the tightest binders. This inconsistency makes the PROTAC development 
process difficult, because rational design and efficacy prediction based on established 
target binders is nearly impossible.  
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The last part of a PROTAC chimera is the linker between the warhead and E3 
binding domain. The composition of the linker is extremely important, not only for 
degradation, but also for cell permeability and in vivo clearance of the PROTAC86,105. 
Initially, a peptidic linker was used, but low cell permeability and high cleavage rate led 
to small molecule linkers being favored105. Another requirement for the linker is enough 
length and flexibility to bridge the interaction between the target and E3 ligase and allow 
for sampling of the conformational landscape104,106. 
Because PROTACs are modular, all iterations of a PROTAC must be tested 
empirically. Each piece of the molecule (E3 binder, warhead, and linker) affects how well 
it binds to and ubiquitinates its targets104,106-108. When examining patterns to correlate 
binding efficiency with degradation, one study found that the major factor in 
ubiquitination ability was the formation of a stable ternary complex between the target, 
PROTAC, and E3 ligase96,109. The determining factor for efficient degradation was 
actually a stable protein-protein interaction between the target and the E3 ligase, rather 
than PROTAC affinity for either target or E3. Presumably, changing any of the PROTAC 
domains could alter the structure of the complex, which would change the availability of 
lysine residues in the target or active site in the E396,97. Despite these challenges, 
PROTACs continue to be developed and have been moderately successful in preclinical 
studies110. In fact, the FDA recently approved the first clinical trial based on inducible 
degradation, a PROTAC that depletes androgen receptor for patients with metastatic 
prostate cancer109. 
“TRIM-Away”: Using antibodies to bridge target and E3 
Another recently-developed inducible degradation system takes advantage of an 
E3 ligase involved in the adaptive immune system, tri-partite motif-containing 21 
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(TRIM21), which recognizes the Fc region of antibodies and induces their degradation111. 
During viral infection, antibodies attach to virions and remain attached when the virions 
are endocytosed. In the cytosol, TRIM21 binds to the antibodies and auto-ubiquitinates. 
The whole complex, including the virus protein, then binds to the proteasome and is 
degraded111,112.  
Clift et al redirected this mechanism to deplete specific proteins from cells112,113 
(Figure 2b). In a system called “TRIM-Away”, they overexpressed TRIM21 in cells, 
followed by microinjection with an antibody that binds to a protein of interest. Upon 
introduction of the antibody, concentration of the target protein rapidly decreased in a 
proteasome-dependent manner. Degradation of the target was efficient enough that 
phenotype changes could be readily observed. For example, in mouse oocytes 
overexpressing TRIM21, introduction of anti-Eg5, which targets a mitotic microtubule 
motor protein required for proper spindle polarity114, led to improper spindle formation 
and failure to exit mitosis. Strikingly, the phenotypic effect was as pronounced as that of 
treatment with Eg5 inhibitor monastrol115. TRIM-Away was also effective at inducing the 
degradation of other proteins in cells, including Rec8, mTOR, and IKKa116. 
One limitation to the TRIM-Away system is that TRIM21 must be overexpressed 
in order to induce significant depletion112. The most likely explanation is that TRIM21 is 
degraded along with the antibody and target protein111, so unlike PROTACs, which can 
turn over multiple target proteins88, degradation in the TRIM-Away system is limited by 
the concentration of TRIM21 in the cell. 
Other inducible degradation systems 
Other methods have been developed for depleting proteins, but all of these 
systems require target protein modification. One technique attaches a destabilizing 
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domain (DD) to a protein of interest that unfolds under normal conditions, causing the 
protein to be ubiquitinated and degraded. Often, these domains can be stabilized with a 
small molecule, and thus the stability of the fusion protein can be tuned. An example of 
this is the attachment of a mutated form of FKBP12 to the highly stable yellow 
fluorescent protein (YFP). This fusion is constitutively unstable, but addition of a small 
molecule that binds FKBP12 stabilizes the chimera and confers resistance to 
degradation117.  
It is also possible to target a protein indirectly to the proteasome by taking 
advantage of natural protein-protein interactions. For example, the bacterial proteins 
barnase and barstar interact tightly in the cell. When a ubiquitin chain is attached to 
barnase and an initiation region to barstar, a complex is formed that is recognized by the 
proteasome and barstar is degraded118. Similarly, our lab previously constructed an 
inducible protein degradation system that causes the depletion of ectopically expressed 
substrates119. This system takes advantage of chemical inducers of dimerization, which 
bind two proteins simultaneously. Rad23b’s UBL was attached to one binding partner, 
and as a model target GFP was attached to the other partner. These proteins were co-
expressed in cells, and in the presence of the small dimerization molecule, a complex was 
formed, shuttled to the proteasome, and the GFP domain was degraded.  
Concluding remarks 
Recently, there has been much excitement in the inducible degradation field. By 
depleting proteins, rather than their precursors, the downstream effects of changing 
protein concentration can be directly measured. In addition, most cellular proteins are 
modified post-translationally, which affects their function85. Often, it is a particular 
subpopulation of the target that is relevant to disease or research, so the ability to study 
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just the modified form is useful. This can only be achieved by depleting the protein after 
translation, which limits the usefulness of methods like RNAi and CRISPR and makes 
inducible degradation an attractive option. 
All of the technologies described here have been successful in depleting proteins 
either in vivo or in vitro. However, the methods that degrade endogenous proteins without 
target modification rely on ubiquitination of the target. This is an important distinction 
because of the potential consequences of interfering with the cell’s ubiquitin system. 
Ubiquitin is a signaling molecule for numerous cellular pathways other than proteolysis, 
including DNA damage repair, transcriptional regulation, and membrane trafficking27. 
There are many ways to modify a protein with ubiquitin, and the type of modification 
affects the fate of the target. Therefore, inducing a protein’s ubiquitination does not 
always lead to degradation. The ubiquitin code is still poorly understood and 
manipulating ubiquitination risks unintended side effects. Finally, depleting the ubiquitin 
pool affects cells in a pleiotropic manner and can lead to toxicity120,121. 
To address these limitations, we designed proteasome adaptors that contain a 
UBL domain attached through a linker to an affinity domain that recognizes a protein of 
interest. The UBL from Rad23 binds to the proteasome and has been used successfully in 
other systems to target proteins for degradation119. Because Rad23 is not efficiently 
degraded in the cell62, it should confer resistance to degradation to the entire adaptor. The 
affinity domain we chose is called a monobody, a small protein based on the tenth 
domain of fibronectin type III that has been adapted to bind specific proteins122. As proof 
of concept, we used monobodies that bind the Src homology 2 (SH2) domains of Abelson 
kinase (Abl) and Shp2 phosphatase, both oncology drug targets in their own right123-126. 
In principle, these adaptors should seek out the target of interest and localize it to the 
proteasome for degradation in a catalytic manner, without interfering with ubiquitination.  
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Chapter 2: Results 
DESIGN AND IN VITRO CHARACTERIZATION OF MODEL SUBSTRATES/ADAPTORS 
Background 
To investigate whether our proteasome adaptors can induce degradation of 
proteins, we first tested the system in vitro with purified model substrates, adaptors, and 
proteasome. To do so, we attached a proteasome-binding domain, the UBL domain from 
Rad23, to an affinity scaffold that recognizes a particular target. Many types of affinity 
scaffolds have been developed, including nanobodies127-129, Affibodies130, designed 
ankyrin repeat domains (DARPins)131,132, and others. We chose a small, single-chain 
affinity reagent called a monobody, which is a stably folding protein derived from the 
tenth domain of fibronection type III122,133,134. Monobodies contain seven beta strands 
connected on one side through flexible loops of approximately five to eight amino acids 
long133. Similar to the CDR loops in antibodies, the sequences of these loops can be 
randomized to create a library and then selected to bind specific proteins of interest using 
phage and yeast display methods135. These evolved monobodies bind their targets with 
high affinity and sufficient selectivity to discriminate between members of homologous 
protein families and even PTMs136-138. Unlike antibodies, monobodies contain no 
disulfide bonds and are easily expressed in bacterial systems as stably folded proteins122 
(personal observations). 
We chose to test our system on two well-studied proteins that have been 
prominent targets in cancer drug development efforts: Abelson kinase (Abl) and Shp2 
phosphatase139-141. Abl is a non-receptor tyrosine kinase that plays a key role in myriad 
pathways, including cytoskeleton rearrangement, DNA damage repair, receptor tyrosine 
kinase signaling, chromatin remodeling, and transcriptional regulation, to name a few 142. 
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Just over 1100 amino acids long, Abl protein is approximately 122 kDa and contains 
three N-terminal folded domains: Src-homology (SH) 3, SH2, and a kinase (SH1) domain 
that make up about half of the protein143. At the very N-terminus is a variable region 
(“cap”) that changes depending on exon 1 splicing144. One form contains a myristoylation 
site that, once modified, induces a conformational change in Abl that leads to its 
autoinhibition143,145. The cap in both spliced forms also interacts directly with the SH3 
and kinase domains to inhibit the function of Abl145. This region is critically important to 
prevent oncogenicity and is discussed in more detail below. At the C-terminus is a 
partially folded actin binding domain (ABD) that interacts with the cytoskeleton and 
enables rearrangement and organization146. The ABD also contains a nuclear export 
signal147. Between the folded domains is a long unstructured stretch that contains many 
localization and modification regions. There are three nuclear localization signals, three 
PxxP domains (proline-rich regions that bind to SH3 domains), and three DNA-binding 
motifs that recognize A/T-rich regions, in addition to several phosphorylation sites148.  
The variety of binding motifs and localization signals indicates the complexity of 
Abl signaling, the full scope of which is still being elucidated142. It has been established 
that: Abl stimulates actin polymerization by activating regulators of Arp2/3149; Abl 
phosphorylates the C-terminal repeated domain of RNA polymerase II, indicating a role 
in transcription elongation150; Abl also interacts with the histone acetyltransferase Tip60 
upon DNA damage by ionizing radiation, which suggests a part in DNA damage response 
and histone remodeling151; Abl also binds the receptor tyrosine kinase (RTK) adaptor 
protein Grb2, implicating a function in RTK signaling124. 
Interestingly, though Abl is typically thought of as a potent oncoprotein, 
overexpression of wild-type Abl1 does not lead to cancer142. However, in chronic 
myeloid leukemia (CML), a chromosomal translocation event causes Abl kinase to be 
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translated as a fusion protein C-terminally to Breakpoint Cluster Region (BCR-Abl). 
Although BCR has been studied mostly in the context of its fusion to Abl, BCR is a 
signaling protein in its own right that contains N-terminal serine/threonine kinase and 
dimerization domains upstream of both guanine nucleotide exchange factor (GEF) and 
GTPase-activating (GAP) domains142,152,153. The translocation occurs between 
chromosomes 22 and 9 and forms a neo-chromosome dubbed the “Philadelphia 
chromosome”154. The breakpoint in BCR can occur at several sites, each of which leads 
to a different sized fusion protein155. Amazingly, however, the Abl portion of the 
chimeric mRNA always begins at exon 2148. The reason for this is unknown; while the 
chromosomal translocation usually occurs between exon 1a and 1b of Abl, the resulting 
mRNA invariably excludes exon 1148. As mentioned earlier, Abl normally exists in an 
autoinhibited state with the N-terminal domain (encoded by exon 1) bound to the 
functional domains; when expressed as a fusion protein with BCR, the self-regulation is 
abrogated because the main autoinhibitory mechanism is deleted. The most significant 
consequence of this is a marked increase in kinase activity, including phosphorylation of 
other proteins as well as autophosphorylation148. Three main routes to transformation 
occur upon BCR-Abl expression: decreased adhesion to the extracellular matrix and bone 
marrow stroma cells156; increased mitogen-activated signaling through upregulated MAP 
kinase, Jak/STAT, and PI3 kinase pathways157-162; and inhibition of apoptosis163,164. 
Taken together, the deregulation of Abl signaling upon expression of BCR-Abl is the 
causative agent for CML and other leukemias69,139. 
The other target we chose to investigate was Shp2 phosphatase. Shp2 is an 
approximately 68 kDa protein consisting of three domains: two tandem SH2 domains (N-
SH2 and C-SH2, respectively) connected to a phosphatase domain. Like Abl, Shp2 is 
normally autoinhibited in a conformation where the SH2 domains bind to the phosphatase 
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domain and obstruct the catalytic site165. Shp2 is activated by engaging phosphotyrosine 
motifs through its SH2 domains166. Upon binding, the intramolecular interaction is 
disrupted and the active site is exposed166. While phosphatases as a class of proteins are 
often considered tumor suppressors due to inhibition of cell growth signal pathways167, 
Shp2 is somewhat unique in that it was the first reported tyrosine phosphatase 
oncoprotein168,169. Overexpression of Shp2 is associated with several types of cancers, 
including breast cancer68,170,171 and glioblastoma multiforme172, and activating mutations 
in Shp2 cause Noonan and LEOPARD syndromes as well as childhood cancers173. 
Shp2’s oncogenic propensity is mostly due to its role in Ras activation174. Shp2 binds to 
RTKs and recruits the adaptor proteins Grb2 and Grb2 associated binder (GAB)175,176. 
Shp2 dephosphorylates Ras, which attenuates the interaction with its GTPase-activating 
protein (GAP)172. This in turn maintains Ras in an active state and promotes downstream 
proliferative signaling through the mitogen activated protein kinase (MAPK) pathway 
(@@Milburn Science 1990). Inhibition of Shp2 has been shown to reduce growth and 
metastasis of cancers that rely on RTK signaling168,172,174. 
To target these two proteins for degradation, we generated adaptors containing 
monobodies that recognize the Src-homology 2 (SH2) domains of Abl or Shp2137,138. In 
principle, the adaptors should bind to the target protein, bring it to the proteasome, then 
recycle back into the cell (Figure 3a, b). 
Construction of adaptors and model substrates 
In order for a protein to be effectively degraded, the substrate must be positioned 
properly on the proteasome so that the initiation region is accessible for 
translocation15,118,177. Therefore, we designed and tested several conformations of adaptor 
and substrate domains (Figure 3a). We made simplified model substrates containing just 
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the SH2 domain of Abl. As a readout for substrate concentration, we fused monomeric 
superfolder (ms) GFP to the C-terminus of the SH2 domain, followed by a 35-amino acid 
unstructured initiation region derived from cytochrome b2 that is known to support 
efficient degradation (the whole substrate is referred to as SH2-GFP-tail)13,14 (Figure 3). 
We used msGFP because it is a very stable protein but can be degraded when attached to 
an initiation region178. We also tested a circular permutant of GFP (Cp8) that is less stable 
but found no difference in degradation patterns (Appendix A)179,180. 
To optimize model substrate positioning, we created four iterations of the adaptor 
by changing the arrangement of the two adaptor domains and the linker between them 
(Figure 3a). The first configuration contained a simple Gly-Ser/Thr linker (GGSGGT) 
with the S. cerevisiae Rad23 UBL domain (aa 1-77) at the N-terminus and the Abl SH2 
monobody at the C-terminus. We then interchanged the UBL and monobody domains 
and also replaced the short linker in both configurations with a longer flexible linker 
derived from the region between the UBL and first UBA domain of Rad23 (aa 77-144). 
We chose this linker because it is known to be resistant to proteasomal degradation and 
should thus confer stability to the adaptor62. A longer linker also gives flexibility to the 
adaptor, which in theory allows the adaptor-substrate complex to sample multiple 
positions on the proteasome. As a negative control, we designed a non-binding adaptor in 
which the monobody was mutated at Tyr87 to alanine. This completely abolished binding 
to the SH2 domain137. We also created and tested 4 geometries of the model substrate, the 
results of which are discussed in Appendix A. 
I first optimized the expression and purification of the adaptors and substrates. I 
fused the constructs to a C-terminal chitin-binding domain (CBD), which binds to chitin 
resin and self-cleaves in the presence of reducing agent181. I also tried substituting just a 
His6 tag on the N- or C-terminus, but found that the yield, purity, and stability of the CBD 
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fusions were much greater, despite the fact that the CBD fusions required overnight 
cleavage in reducing conditions. The adaptors also contained an N-terminal FLAG tag 
and the substrates contained an N-terminal HA tag so that they could be monitored by 
Western blot. Next, I purified FLAG-tagged (3xFLAG-Rpn11) proteasome from yeast 
using an established method (see Materials and Methods), and found that the final 
product was highly stable and retained activity after freeze-thaw or left overnight at 4°C. 
Because the proteasome is a very large complex, and most likely copurifies with 
proteasome-binding proteins (e.g. Ubp6), the concentration of proteasome was estimated 
based on a size of 2.5 MDa but was by no means an exact concentration. 
After purification of all components, we first tested the UBL-GGSGGT-
monobody adaptor in vitro with the Abl SH2 model substrate on a plate reader, with the 
decrease in GFP fluorescence as a readout for substrate depletion. We incubated adaptor 
and substrate together before adding proteasome and immediately began the assay. We 
found that the model substrate was degraded only in the presence of adaptor and 
proteasome (Figure 4a). This suggested that degradation of substrate was dependent on 
both adaptor and proteasome. In addition, degradation of substrate increased at higher 
concentrations of adaptor, although there was a point at which more adaptor led to 
decreased substrate depletion. One explanation is that at a high enough concentration of 
adaptor, the proteasome is saturated and model substrate degradation rate is determined 
only by substrate turnover. Another explanation could be related to the “hook effect” 
which occurs when one protein acts as a linker between two others. At high enough 
concentrations of the linker protein, formation of the ternary complex actually decreases 
due to competition for binding between intermediate species182,183. This results in a 
falsely low final readout. In this case, the adaptor acts as the linker protein between the 
substrate and proteasome. At high adaptor concentrations, there is less 
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substrate•adaptor•proteasome complex formed, which decreases both the total amount of 
degradation and the initial rate. This was most noticeable when the nanomoles of 
substrate degraded were plotted against the concentrations of adaptor (Figure 4b). At low 
concentrations of adaptor (below the concentration of substrate), there is a 
superstoichiometric amount of substrate degraded. Above the concentration of substrate, 
degradation levels off and decreases slightly at the highest concentrations of adaptor.  
The model substrate was degraded completely, as no intermediate fragments were 
detected in a Western blot against the N-terminal hemagglutinin (HA) tag on the 
substrate (Figure 5, above). Over the course of 75 minutes, nearly all of the substrate was 
depleted, as compared to proteasome loading control (Figure 5, below). As expected, the 
FLAG-tagged adaptor was not degraded over the course of the assay (Figure 5, above). 
We next tested the other adaptor configurations (Figure 6). Surprisingly, all of the 
adaptor configurations were able to deplete the substrate to a certain extent, suggesting 
that the adaptors are flexible enough to position the substrate properly even with a short 
linker, or else the adaptor can bind to multiple locations on the proteasome to optimize 
positioning. We found that the substrate was degraded most and had the highest initial 
rate in the presence of the original adaptor design, UBL-GGSGGT-monobody (Figure 6). 
We therefore used the original geometry for the rest of the studies. Having a longer linker 
was worse than a short one for both domain configurations, suggesting that there is an 
optimum spacing between the UBL and monobody. This was somewhat surprising, 
because we used the native linker between Rad23’s UBL and the first UBA domain. The 
linker seems to be important for the endogenous protein, so we expected it to help in our 
adaptors62. This discrepancy could be explained by the fact that native Rad23 binds to 
ubiquitinated proteins with varying chain length and must be flexible enough position the 
substrates at the translocation entrance184. 
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Figure 3: Model adaptor configurations and schematic 
A) Adaptor and model substrate configurations. B) Schematic of model substrate and 
adaptor; adaptor binds to target through affinity domain (monobody) and then binds to 
proteasome via Ubiquitin-Like (UBL) domain. Substrate is degraded, while adaptor is 
not. 
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Figure 4: Model substrate is degraded in vitro in presence of adaptor. 
A) Left: Fluorescence assay monitoring substrate through GFP fluorescence over time. 20 
nM SH2AbL-GFP-tail was incubated with indicated concentrations of adaptor in the 
presence or absence of 40 nM proteasome. Positive control: UBL-GFP-90aa tail. Right: 
Initial rate of degradation increases with concentration of adaptor until saturation of 
binding occurs. B) Nanomoles of substrate degraded plotted versus adaptor 
concentration. 
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Figure 5: Western blot confirmation of model substrate depletion 
Above: Western blot of HA-tagged model substrate and FLAG-tagged adaptor and 
proteasome (Rpn11). 20nM substrate were incubated with 160nM adaptor and 25nM 
proteasome and samples were taken at indicated time points. Asterisk indicates non-
specific band. Below: Quantification of model substrate bands normalized to the first lane 
as a percentage of Rpn11 band. 
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Figure 6: Testing adaptor configuration in vitro. 
A) Fluorescence plate reader assay with 20nM SH2AbL-GFP-tail, 160nM adaptor, with 
and without 25nM proteasome. B) Initial rates of different adaptor geometries confirm 
that UBL-mB is the fastest adaptor. Bars represent mean initial rate of three separate 
reactions +/- SD.  
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TESTING ADAPTOR-MEDIATED DEGRADATION OF MODEL PROTEINS IN CELLS 
Adaptor transfection leads to depletion of model substrate in HEK293 cells 
After successfully degrading the SH2-GFP-tail model protein in vitro, we next 
tested the system in HEK293 cells. We integrated the Abl model substrate (SH2-GFP-
tail) under a cytomegalovirus (CMV) promoter into HEK293 cells using the Flp-In 
system119 (Figure 7a) and confirmed its stable expression via Western blot (Figure 7b). 
The cells showed green fluorescence (Figure 8a); however, as the cells were passed, the 
fluorescence decreased and split into high, medium, and low fluorescence populations, 
which became more distinct as the passage number increased (not shown). This could be 
due to CMV promoter silencing, a common phenomenon observed in human cells when 
the CMV promoter is methylated, and it increases over time and passage number185. 
Therefore, we only used cells at low passage. 
We then modified the in vitro adaptor construct for the cellular assay in two ways. 
First, we replaced the yeast Rad23 UBL with the human homolog Rad23b (hHR23B) 
UBL domain, which binds to the human proteasome59. We also added an mCherry 
fluorescent readout after an internal ribosome entry site (IRES)119 so we could analyze 
cells that expressed the adaptor by flow cytometry (Figure 7a). 
Substrate-binding or non-binding (mutated monobody) adaptor constructs were 
transfected into integrated or host cells and 72 hours later the cellular fluorescence was 
measured (Figure 8a). Only cells that were mCherry-positive (expressing adaptor) were 
analyzed. We found a four-fold decrease in median GFP fluorescence (substrate levels) in 
the cells with binding adaptor as compared to non-binding adaptor (Figure 8b), indicating 
that the model protein was depleted by approximately 70% only in the presence of 
binding adaptor. We then sorted and collected the adaptor-transfected (mCherry-positive) 
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cells and analyzed substrate amount by Western blot (Figure 8c). In agreement with the 
flow cytometry data, we saw approximately 60% less substrate in the presence of binding 
adaptor as compared to non-binding adaptor, though this experiment was performed 
once. Again, the model protein was degraded completely as no intermediate fragments 
were detected (Figure 8c). As expected, the FLAG-tagged adaptor was not degraded and 
remained stable in the cells (Figure 8c). 
  
 29 
Figure 7: Design of model substrate and adaptor constructs and expression in cells 
A) Schematic of integrated substrate construct and transiently transfected adaptor 
plasmid. Both adaptor and substrate were expressed under a CMV promoter. GFP-
positive cells were selected for using hygromycin. B) Western blot confirming that 
substrate was integrated. 
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Figure 8: Degradation of Abl model substrate in cells. 
A) Overlaid flow cytometry scatter plots with GFP fluorescence (substrate) on the x-axis 
and mCherry fluorescence (adaptor) on the y-axis. Each dot represents one cell. Orange: 
Figure 8: continued page 31 
 
Non-binding Binding
0
10000
20000
30000
M
ed
ia
n 
G
FP
 fl
uo
re
sc
en
ce
 (A
U
)
P = 0.0002
***
23503
6180
Background
Cells
Binding
Adaptor
Non-binding
Adaptor
# 
ce
lls
GFP Fluorescence (target)
Transfected
cells
GFP Fluorescence (target)
m
C
he
rr
y 
flu
or
es
ce
nc
e 
(a
da
pt
or
)
A
B
IB: GFP (substrate)
Ve
cto
r
No
n-b
dg
Ad
ap
tor
Bd
g 
Ad
ap
tor
IB: Actin
70
38
50
30
8 IB: FLAG (adaptor)
Vector Non-
binding
Binding
0
20
40
60
80
100
%
 re
m
ai
ni
ng
100
39
C
 31 
Host HEK293 Flp-In™ cells transfected with empty vector indicate background 
fluorescence. Blue: Integrated cells transfected with non-binding (UBL-HA4Y87A) 
adaptor. Red: Integrated cells transfected with binding (UBL-HA4) adaptor. Red box 
indicates transfected (mCherry positive) cells. B) Left: Histogram of GFP fluorescence of 
host cells and integrated cells transfected with non-binding and binding adaptors. Colors 
as in A. Right: Median GFP fluorescence values after binding or non-binding adaptor 
transfections plotted for four independent experiments. Bars represent mean +/-SD. P 
value was derived from unpaired two-tailed t-test. C) Left: Transfected cells (red box in 
B) were sorted and collected, and cell lysates were immunoblotted for GFP (substrate), 
FLAG (adaptor), and actin. Right: ImageJ analysis of blot on left representing % GFP 
signal remaining after empty vector, non-binding, and binding adaptor transfections, 
normalized to actin, where vector was set to 100%. 
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TESTING ADAPTORS ON SHP2 PHOSPHATASE 
Developing and testing Shp2 model substrates in vitro 
For the in vitro and initial in-cell tests of our adaptors, we used the SH2 domain 
from Abl kinase as our model substrate and the Abl-binding monobody in the adaptor. To 
test the versatility of our system, we chose two other monobodies that bind to a different 
target, Shp2 phosphatase. Shp2 contains two tandem SH2 domains (SH2N and SH2C), 
each of which is recognized by a distinct monobody138. Therefore, we created two model 
substrates, Shp2 SH2N- or Shp2 SH2C-GFP-tail to test both in vitro and in cells.  
Upon purification of the SH2N-GFP-tail, I found that the protein was unstable, 
despite trying several methods of purification (His-tagged followed by size exclusion or 
chitin purification) and rounds of optimization. The protein was degraded by proteasome 
independently of the adaptor (although not without proteasome), suggesting that the 
substrate was at least partially unfolded (data not shown). It is possible that even in the 
absence of adaptor, the proteasome has some affinity to the initiation region, as it has 
been shown that the proteasome shows preference for certain sequences, and our 
initiation region was created with that in mind14. 
The SH2C-GFP-tail substrate was more stable when purified, so I used that 
substrate to test the versatility of the system in vitro. I created an adaptor that binds to the 
C-terminal Shp2 SH2C via the monobody Cs3138. The substrate degraded approximately 
15% in the absence of adaptor or presence of non-binding adaptor (Figure 9). However, 
the model substrate degraded further in the presence of binding adaptor and proteasome 
(Figure 9). There was dose-dependence observed, which saturated at approximately 
40nM adaptor. The saturation of the Shp2 model substrate degradation occurred at a five-
fold lower concentration of Shp2 adaptor than the Abl adaptor for the Abl model 
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substrate (Figure 4, 9a). This agrees with the five-fold lower Kd of Cs3 to Shp2 SH2C 
than the Abl monobody to SH2Abl.137,138 
To see if the Shp2 adaptor acted in a catalytic manner, I plotted the amount of 
substrate degraded versus the amount of adaptor present (Figure 9c). As in the Abl 
experiments, the amount of substrate degraded increased with increasing adaptor up to a 
point (~40nM adaptor). At low concentrations of adaptor (less than substrate), the adaptor 
degraded a superstoichiometric amount of substrate. However, once the adaptor 
concentration became higher than the initial substrate concentration, the amount of 
substrate degraded leveled off and adding more adaptor did not increase depletion. This 
could be due to either saturation of binding to the proteasome (which was 25nM in the 
reaction) or to the hook effect, where high concentrations of a linker protein can be 
autoinhibitory182,186. Thus, there exists an optimum concentration of adaptor to induce the 
maximum amount of substrate depletion. 
Shp2 Model Substrates Are Degraded in Cells Upon Adaptor Transfection 
I next tested whether the Shp2 adaptors could deplete the Shp2 model substrates 
in cells. I created stable HEK293 cells containing model substrates with either the N-
terminal or C-terminal SH2 domain (Shp2 SH2N- or Shp2 SH2C-GFP-tail) with the Flp-In 
System as in Figure 3a. I transfected the corresponding adaptor constructs, which bound 
to either the SH2N or SH2C domain (but not both138) and contained the mCherry 
fluorescent readout as in Figure 3a. As a control, I used the same non-binding (mutated) 
adaptor as for the Abl experiments. Upon transfection of SH2N-binding adaptor, there 
was a three-fold decrease in SH2N-GFP-tail fluorescence in transfected (mCherry-
positive) cells as compared to non-binding adaptor (Figure 10a). When SH2C-binding 
adaptor was transfected into cells expressing SH2C substrate, GFP fluorescence decreased 
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Figure 9: Degradation of Shp2 model substrates in vitro. 
A) Left: Fluorescence assay monitoring substrate through GFP fluorescence over time. 20 
nM SH2AbL-GFP-tail was incubated with indicated concentrations of binding and non-
binding adaptor in the presence or absence of 25nM proteasome. Positive control: UBL-
GFP-90aa tail. Right: initial rate of degradation plotted against concentration of adaptor. 
B: As in A, but for lower concentrations of adaptor. C) Nanomoles of substrate degraded 
plotted versus adaptor concentration.  
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by 2.8-fold in transfected cells (Figure 10b). I then sorted and collected the transfected 
cells and probed substrate expression levels on a Western blot with a GFP antibody. The 
depletion of substrate was confirmed by Western blot (Figure 10c, n = 1).  
Testing the adaptors on endogenous Shp2 
The final step in this project was to verify whether the adaptors could lead to 
depletion of full-length, endogenous protein. I chose to use Shp2 as the target because it 
is ubiquitously expressed as a cytosolic protein187,188 and is readily detectable in 
HEK293T cells with Western blot (Figure 11a). Using immunoprecipitation I confirmed 
that the SH2N- and SH2C-binding adaptors bound to full-length Shp2, but non-binding 
adaptor does not (Figure 11a). All adaptors (including non-binding) bind to the 
proteasome (Figure 11a). When I pulled down the adaptor via its FLAG tag, both Shp2 
and proteasome pulled down with it. However, when I pulled down Shp2, no proteasome 
bad was detected. Presumably, this is because once the Shp2-adaptor complex binds the 
proteasome, Shp2 is immediately translocated and degraded.  
I transfected SH2N-binding or non-binding adaptor into HEK293T cells and found 
that the adaptor depletes endogenous Shp2 levels by about 50% in Western blot assay 
(Figure 11b, c). As an orthogonal readout for Shp2 levels, I also developed a protocol for 
immunofluorescence followed by flow cytometry; however, the antibody bound at the 
same region as the binding adaptor and therefore I could not use the results from this 
assay (described further in Appendix B). Despite this, the Western blot assay consistently 
showed depletion of endogenous Shp2 from cells (Figure 11b, c). 
There are several possible reasons why the adaptors did not deplete endogenous 
proteins as well as model proteins. First, the adaptors may not bind as tightly to the full-
length Shp2 protein as to the SH2 model protein. Indeed, the monobodies themselves 
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Figure 10: Degradation of Shp2 model substrates in cells. 
A) Left: Overlaid flow cytometry scatter plots of Shp2 SH2N-GFP-tail integrated cells 
with GFP fluorescence (substrate) on the x-axis and mCherry fluorescence (adaptor) on 
Figure 10: continued page 37 
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the y-axis. Orange: Host HEK293 Flp-In™ cells transfected with empty vector indicate 
background fluorescence. Blue: Integrated cells transfected with non-binding (UBL-
HA4Y87A) adaptor. Red: Integrated cells transfected with binding (UBL-HA4) adaptor. 
Red box indicates transfected (mCherry positive) cells. Middle: Histogram of GFP 
fluorescence of host cells and transfected integrated cells with non-binding and binding 
adaptors. Colors as in B. Right: Median GFP fluorescence values after binding or non-
binding adaptor transfections plotted for four independent experiments. Bars represent 
mean +/-SD. P value was derived from unpaired two-tailed t-test. B) As in A, for Shp2 
SH2C-GFP-tail substrate. C) Left: Transfected cells (red box in C) were sorted and 
collected, and cell lysates were immunoblotted for GFP (substrate) and FLAG (adaptor). 
Asterisk indicates BSA from leftover media in sample. Right: ImageJ analysis of blot on 
left representing % GFP signal remaining after empty vector, non-binding, and binding 
adaptor transfections, where vector was set to 100%. 
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Figure 11: Shp2 adaptors bind to and degrade endogenous Shp2. 
A) 293T cells were transfected with vector, non-binding adaptor-IRES-HA-Shp2, Shp2 
SH2N-binding adaptor-IRES-HA-Shp2, or Shp2 SH2C-binding adaptor-IRES-HA-Shp2. 
Lysates were immunoprecipitated with either HA beads (pulling down Shp2) or FLAG 
beads (pulling down adaptor) according to manufacturer’s instructions and blotted for 
FLAG, HA, proteasome (Rpn8), and actin. B and C) Top: Western blots of two 
independent transfection experiments. 293T cells were transfected with vector, non-
binding, or Shp2 SH2N-binding adaptor. Lysates were blotted for Shp2, FLAG (adaptor), 
and actin. Bottom: ImageJ quantification of Shp2 band intensity normalized to actin and 
vector bands. 
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bind more tightly in vitro to a single SH2 domain than to tandem SH2 domains138. In 
addition, cellular Shp2 exists in a “closed”, auto-inhibited conformation until it binds to a 
phosphorylated protein, upon which the SH2 domains dissociate from the phosphatase 
domain and reveal the active site165. The Shp2 monobodies preferentially bind the closed 
conformation138, which may not be the optimal conformation for degradation. Further, 
while Shp2 contains a C-terminal unstructured region165, this may not serve as an 
efficient initiation region for the proteasome. 
CONCLUSIONS 
I have developed a method for the depletion of proteins from cells by targeting 
them directly to the proteasome. This system uses protein adaptors which bind to the 
proteasome through a UBL domain and simultaneously bind to a protein of interest 
through an affinity domain. I showed that this method works well to degrade model 
substrates by ~70-80% in vitro. The most likely explanation for the 20% of substrate 
remaining is that some of the substrate was oligomerized or aggregated. All fluorescent 
proteins are prone to oligomerization and aggregation189, which are difficult for the 
proteasome to degrade190. 
Interestingly, we saw that the amount of depletion and initial rate increased with 
adaptor concentration up to a certain point, after which substrate degradation decreased. 
One explanation for this could be related to the “hook effect” which occurs when one 
protein acts as a linker between two others. At high enough concentrations of the linker 
protein, formation of the ternary complex actually decreases due to competition between 
intermediate species183,186, resulting in falsely low final readout. In this case, the adaptor 
acts as the linker protein between the substrate and proteasome. At high adaptor 
concentrations, there is less substrate•adaptor•proteasome complex formed, which 
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decreases both the total amount of degradation and the initial rate. We also found that the 
configuration of the adaptor domains (UBL, linker, monobody) affected how well the 
model substrates were degraded. This could be due to the positioning of the substrate on 
the proteasome; the adaptor-substrate complex must bind in such a way as to make the 
initiation region accessible for unfolding and translocation and only certain 
configurations were able to do so.  
The adaptors also depleted integrated model substrates in HEK293 cells by 60-
75%. While this was not quite as much as in the in vitro studies, this could be explained 
by differential expression patterns of adaptor and substrate. The substrate was diffuse 
throughout the cell (data not shown), but because we used an independent readout for 
adaptor expression (mCherry expressed from an IRES promoter), we were unable to 
monitor the location of the adaptor. It is possible that the adaptor remained in the cytosol, 
in which case any nuclear substrate would remain undegraded.  
Finally, the adaptors were able to deplete endogenous Shp2 levels by ~50%. One 
explanation is that the adaptors may not recognize full-length Shp2 protein as easily as 
SH2 model protein. In vitro, the monobodies showed poorer binding to a model substrate 
containing the tandem SH2 domains than to either SH2 by itself138. In addition, most of 
the Shp2 population in cells exists in a “closed”, auto-inhibited conformation until it 
binds to a phosphorylated protein. The whole protein then undergoes a conformational 
change where the SH2 domains dissociate from the phosphatase domain to reveal the 
active site165. The Shp2 monobodies preferentially bind the closed conformation138, 
which may not be the optimal conformation for degradation. Further, while Shp2 contains 
a C-terminal unstructured region of approximately 70 amino acids165, this may not serve 
as an efficient initiation region for the proteasome. 
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One feature of this system is that it bypasses the need for ubiquitination because 
our adaptors were designed to interact directly with the proteasome. It may be 
advantageous to have a depletion method that does not rely on ubiquitination because of 
the pleiotropic effects of depleting the ubiquitin pool. Our system is versatile as well, as 
the target-binding domain can be switched out to virtually any affinity scaffold. In this 
work, we showed depletion of three different model proteins with three affinity domains 
as well as an endogenous protein. Future work includes testing our adaptors with other 
affinity scaffolds, such as nanobodies. A further avenue is to explore delivery of the 
adaptors into cells at the protein, rather than plasmid, level. 
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Chapter 3: Conclusions and Future Directions 
The ability to deplete a protein from cells is extremely useful for many reasons, 
including studying the protein’s function and treating diseases caused by malfunctioning 
or overexpressed proteins. The most common methodology uses RNAi to inhibit 
synthesis of specific proteins. However, inhibiting the expression of a protein does not 
allow for analysis at the post-translational level. Recently, the idea to deplete the protein 
via the ubiquitin proteasome system (UPS) has gained traction and several systems have 
been developed to do so. Here, I have presented a novel technology for degradation of 
specific proteins, both in vitro and in cells. The mechanism uses proteasome adaptors that 
recognize particular targets and shuttle them to the proteasome for degradation.  
Our system centers around the 26S proteasome, a macromolecular, ATP-
dependent protease which is responsible for degrading hundreds of cellular proteins in a 
tightly-controlled manner. The proteasome is integral to nearly every process in the cell, 
including cell cycle, transcription and translation, and signaling networks. As a main 
regulator of protein concentration, the proteasome must be versatile enough to degrade all 
types of domains, yet specific enough to degrade only proteins that are unnecessary or 
malfunctioning. Proper timing and specificity of proteasomal degradation is extremely 
important, and dysregulation of the UPS has been implicated in many diseases. For 
example, neurodegenerative diseases can be caused by accumulation of aggregated 
proteins. Although there is evidence that the protein aggregates are tagged with ubiquitin, 
the proteasome is unable to degrade them191,192. It is possible that the ubiquitinated 
aggregates never reach the proteasome; therefore, shuttling them directly to the 
proteasome could help to clear the aggregates. 
The proteasome has also been targeted in drug development for many years. 
Proteasome inhibitors have been successful in treating various diseases such as cancer 193. 
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For example, Velcade (Bortezomib) has seen clinical success in the treatment of multiple 
myeloma194. The rationale for inhibiting the proteasome is that damaged proteins, which 
are more prevalent in cancer cells than healthy ones, will build up in the cancerous cells 
and trigger the apoptotic pathways195. 
Recently, the notion of harnessing the proteasome’s power to degrade specific 
proteins has been examined. Several technologies have been developed that induce 
degradation of certain proteins. An advantage to depleting the proteins, rather than 
inhibiting them, is that they are completely destroyed, and therefore have no potential to 
cause further harm in the cell. The best-characterized technique involves PROTACs, 
small molecules which link a target with an E3 ligase88. The E3 ubiquitinates the target 
which leads to the target’s degradation. Various PROTACs have been created using 
different E3 ligases, and one was recently approved to begin clinical trials86,109. An 
advantage to PROTACs is that as small molecules, PROTACs have increased cell 
permeability over protein therapeutics. Also, the PROTAC is not degraded with the target 
and acts catalytically to induce ubiquitination of multiple proteins88. PROTACs have 
been limited in their versatility, however. They contain 3 modules, a warhead (target-
binding domain), an E3-binding domain, and a linker in between. Each of the domains 
must be optimized in the context of the entire molecule106. The E3, and any associated 
E2s, must have access to a lysine residue on the target. Therefore, the optimal ternary 
conformation is extremely important but is difficult to predict. In addition, PROTACs are 
limited by the availability of both E3-binding and target-binding ligands. Developing new 
binding molecules is time intensive and cost prohibitive102, and the mere fact that a 
compound binds does not mean that it will make an effective PROTAC module104. 
Finally, PROTACs rely on ubiquitination of the target. Ubiquitin is a signaling protein 
involved in myriad pathways, and a clear understanding of the ubiquitin code remains 
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elusive. Manipulating the ubiquitin pool may cause pleiotropic effects that cannot be 
predicted121. Nonetheless, PROTACs have overcome many obstacles and remain the 
most promising therapeutic for inducible degradation. 
Another recently developed methodology uses an E3, TRIM21, that naturally 
targets antigen-bound antibodies to the proteasome for destruction111. In this system, an 
antibody that recognizes a particular protein is introduced into the cell and is in turn 
recognized by TRIM21. The E3 then autoubiquitinates and the whole complex binds to 
the proteasome and is degraded. Initial experiments show promise for inducing the 
degradation of a wide variety of proteins. An advantage is that antibodies are relatively 
easy to generate and commercially available and validated for thousands of proteins. 
Again, however, the system relies on ubiquitination of the target and has the same 
potential risks as PROTACs. Another disadvantage is that the E3 ligase is degraded along 
with the antibody and target and therefore TRIM21 must be overexpressed to be 
effective112. 
Here I have introduced a new method for inducing degradation of specific 
proteins based on proteasome adaptors. I have constructed chimeric shuttle proteins 
(adaptors) that consist of a recognition domain to select the target protein and a 
proteasome-binding element that brings the target to the cell’s degradation machinery for 
hydrolysis. I analyzed the system both in vitro and in cells and showed depletion for three 
model proteins and an endogenous protein.  
This strategy diverges from traditional protein depletion methods in several ways. 
For one, the adaptors are engineered to function as catalytic molecules that link a target 
directly to the proteasome, thus circumventing the ubiquitination pathway. I based the 
adaptor design on a natural proteasome adaptor, human Rad23b (hHR23B), which brings 
ubiquitinated proteins to the proteasome but escapes degradation itself62. Conferring 
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stability on the adaptors allows them to turn over multiple substrates, as shown in Figures 
4 and 9. The catalytic nature means that a lower concentration of adaptor is required to 
degrade the substrate as compared to traditional, stoichiometric inhibitors. Using a UBL 
domain instead of ubiquitination could help prevent any potential negative effects of 
manipulating the ubiquitin pool. In addition, because many disease-related cellular 
aggregates colocalize with ubiquitin but fail to degrade, having a different method to 
target them to the proteasome may help to clear them. 
The adaptors can also be engineered to recognize nearly any protein of interest. 
For target binding, I used previously-designed affinity domains, monobodies, which are 
derived from the tenth domain of fibronectin type III and can be evolved in vitro to bind 
almost any protein and even to recognize specific PTMs133,136,196,197. Further, adaptors act 
directly on the target protein, so depletion is not limited by the target’s intrinsic turnover 
rate. In principle, the adaptors should work in a complementary way to RNAi, as they act 
through different cellular mechanisms. Using both technologies in combination promises 
synergistic effects198. 
This system is versatile as well, as the target-binding domain can be switched out 
to virtually any affinity scaffold. In this work, I showed depletion of three different model 
proteins with three affinity domains. However, all of the domains were based on the 
monobody scaffold. There are many other protein interaction domains that have been 
developed against myriad proteins199,200. Many of these interaction domains were 
designed to inhibit the function of the target protein, but the scaffolds for these adaptors 
need not be limited to inhibitors. Future work includes testing our adaptors with other 
affinity scaffolds, such as nanobodies. A further avenue is to explore delivery of the 
adaptors into cells at the protein, rather than plasmid, level. This would be useful because 
delivery of the protein allows for control of adaptor concentration in the cell. The 
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adaptors were transiently transfected into cells, and thus the amount of adaptor could not 
be tuned. Another option would be to express the adaptors under control of an inducible 
promoter such as Tet On and titrate their levels with different amounts of inducer. 
In conclusion, I have developed a method to artificially deplete specific proteins 
from cells using the intrinsic cellular degradation machinery, the 26S proteasome. The 
technology is based on proteasome adaptors, consisting of a UBL attached to an affinity 
domain, which bind to a protein of interest and shuttle it to the proteasome for 
destruction. This system is ubiquitin-independent, versatile, and robust. The adaptors 
developed in this study induced depletion of three different proteins both in vitro and in 
cells. Beyond just showing degradation of specific targets, my findings also underscore 
the importance of proper substrate positioning on the proteasome. This system could be 
used in many ways, including studying protein function and stopping the action of 
disease-causing proteins. 
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Chapter 4: Materials and Methods 
In vitro substrate and adaptor plasmid design: In vitro constructs were cloned 
into the second multiple cloning site in a pETDUET vector with a C-terminal Chitin 
Intein binding domain tag followed by a 6x His tag and expressed from the T7 promoter. 
Constructs were cloned via assembly PCR. Substrates contained an N-terminal HA tag 
followed by the SH2 domain (Abl1: aa 127-217; Shp2 SH2N: aa 1-103; Shp2 SH2C: aa 
97-217) and monomeric superfolder GFP (msGFP) with a C-terminal 35 amino acid tail 
derived from cytochrome b2 that served as an initiation region13,177. Adaptors had an N-
terminal FLAG tag followed by the UBL from S. cerevisiae Rad23 (aa 1-77) fused to a 
monobody through a GGSGGT linker. The binding monobodies were HA4 (Abl1), Nsa1 
(Shp2 SH2N), and Cs3 (Shp2 SH2C) and the non-binding monobody was HA4(Y87A) 
which does not bind to Abl SH2 domain137,138. 
  
Antibodies: Primary antibodies used were Abl (mouse, monoclonal, clone 8E9, 
Santa Cruz), HA (mouse, monoclonal, Covance), FLAG (mouse, monoclonal, Sigma), 
Shp2 (mouse, monoclonal, BD), GFP (mouse, monoclonal, Clontech), Actin (rabbit, 
monoclonal, Sigma). Secondary antibodies were goat anti-mouse-IR 800 dye conjugated 
(LI-COR), goat anti-rabbit-IR 700 dye conjugated (LI-COR). 
  
Protein Purification: Yeast proteasome was purified from S. cerevisiae strain 
YYS40 (MATa rpn11::RPN11 3 × FLAG-HIS3 leu2 his3 trp1 ade2 can1 ssd1) by 
immunoaffinity chromatography using FLAG-conjugated M2 agarose affinity beads 
(Sigma)180. Proteasome preparations were analyzed by SDS-PAGE and compared to 
published compositions. Each proteasome preparation was checked for activity by testing 
degradation of the proteasome substrate UBL-GFP-95aa tail.  
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The substrates and adaptors used for the in vitro inhibition assays were 
overexpressed in and purified from E. coli strains BL21(DE3)pLysS or 
Rosetta(DE3)pLysS (Novagen). Bacterial strains were grown in 1 L of 2x YT Media at 
37 °C to an optical density of 0.6-1.0. Protein expression was induced with 0.3 mM 
isopropyl β-D-1- thiogalactopyranoside (IPTG), and incubation continued overnight at 16 
°C. Cells were harvested by centrifugation, re-suspended in cold 20 mM TRIS pH 7.4, 
500 mM NaCl, 10% glycerol and homogenized using the Avestin Emulsiflex C3 (2 
passes) at 15,000 psi. The lysate was cleared by centrifugation at 38,000 x g for 45 
minutes. The cell lysate was incubated with Ni-NTA metal affinity beads (GE 
Healthcare) and nutated for 1 hour at 4 °C. This mixture was applied to a gravity column 
and washed with NPI buffer (50 mM sodium phosphate pH 7.4, 300 mM NaCl) plus 10 
mM imidazole, then NPI plus 20 mM imidazole. The protein was eluted from the resin 
with NPI plus 250 mM imidazole. The elution was desalted by PD-10 desalting column 
(GE Healthcare) and changed into Chitin-column binding buffer (CBB) containing 20 
mM Tris pH 7.4, 150 mM NaCl, 10% glycerol, and 0.5 mM EDTA. This was bound to 
Chitin beads (NEB) then washed with 50 bed volumes of CBB. The protein was eluted 
after an overnight incubation in CBB + 0.1M DTT, and buffer exchanged into a storage 
buffer containing 20 mM Tris pH 7.4, 150 mM NaCl, 10% glycerol.  Protein 
concentration was measured by using either absorbance at 280 nm and the extinction 
coefficient from the proteins’ sequence (ExPASy’s ProtParam) or by the Pierce 660 nm 
protein kit (Thermo Scientific). The identity and purity of purified proteins was 
confirmed by SDS-PAGE. 
 
Substrate Degradation Assay: The degradation of fluorescent substrate in vitro 
was monitored by fluorescence intensity and performed in 384-well plate on plate reader 
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(Infinite M1000 PRO, Tecan) as previously published180. Briefly, substrate and adaptor 
were diluted separately in assay buffer (10 mM Tris HCl, 50mM MgAc, 5% glycerol), 
then 10 µL of adaptor and substrate were mixed and incubated at 30 °C for 5 minutes. 
Proteasome was diluted in assay buffer plus ATP regeneration system180. 20 µL of 
proteasome was added to the adaptor/substrate mixture and the plate was immediately put 
into the plate reader. Fluorescence intensity was read out every minute at the excitation 
wavelength of 388 nm and the emission wavelength of 420 nm for 1-3 hours. Each assay 
was repeated at least two times. Initial degradation rates are given by the slope of the 
decay curves at time zero and are calculated as the product of the amplitude and the rate 
constant of the decay curve determined by nonlinear fitting to a single exponential decay 
in the software package Prism (Graphpad, version 8.0.0). 
For in vitro time course assay, 160 nM adaptor was incubated with 20 nM 
substrate and 25 nM proteasome at 30 °C.  15 µL were taken out at indicated times and 
immediately mixed with sample buffer and boiled to quench the reaction. Samples were 
loaded onto 10% Tris Tricine gels and blotted with indicated antibodies. 
 
Mammalian Construct Design: SH2-GFP-tail substrates were cloned into 
pcDNA5/FRT/TO plasmid (Life Technologies) under a human cytomegalovirus (CMV) 
promoter for integration into Flp-In cells. For adaptors, the human UBL domain from 
hHR23b (aa 1-79) was substituted for the yeast UBL in the in vitro assays. Adaptor 
constructs were cloned into pcDNA3 (Life Technologies) under a CMV promoter and 
contained an N-terminal FLAG tag and C-terminal Internal Ribosome Entry Site (IRES) 
followed by mCherry. 
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Stable Cell Generation: Stable HEK293 Flp-In cells expressing the substrate 
(SH2-GFP-tail) were generated using the Flp-In system (Life Technologies) according to 
manufacturer’s instructions. Briefly, Flp-In 293 host cells were transfected with 1 μg 
substrate DNA in pcDNA5/FRT/TO plasmid and 9 μg pOG44 plasmid encoding Flp 
recombinase (Life Technologies) with Lipofectamine 2000 in a 6-well plate. 24 hours 
later, media was replaced with Dulbecco’s Modified Eagle’s Medium (Gibco) 
supplemented with 10% fetal bovine serum (FBS, Gibco), 1% penicillin/streptomycin 
(pen/strep, Gibco) and 1% glutamine (Q, Gibco) and cells were allowed to recover 
overnight. Cells were trypsinized the next day and plated on 10 cm2 plates in fresh 
medium. Medium was replaced 24 hours later with DMEM supplemented with 10% FBS, 
1% pen/strep/Q, and 200 μg/mL hygromycin B (Gibco). Medium was replaced every two 
to three days with fresh selective medium until colonies formed. All colonies were 
considered to be isogenic and the whole plate was trypsinized and plated into fresh 
selective medium in a 75 cm2 dish, then subcultured according to manufacturer’s 
instructions. Aliquots of cells were frozen in FBS supplemented with 10% DMSO by 
cooling at -1 °C/min at -80 °C and stored in a -150 °C freezer until further use.  
 
Transfections: HEK293 Flp-In Host and SH2-GFP-tail stable cells were 
transfected with either binding (FLAG-hUbL-monobody-IRES-mCherry) or non-binding 
adaptor (FLAG-hUbL-HA4(Y87A)-IRES-mCherry) cloned into pcDNA3 (Life 
Technologies) or empty pcDNA3 with Lipofectamine 2000 reagent according to 
manufacturer’s instructions. 48-72 hours after transfection, cells were washed with ice-
cold D-PBS (Gibco) and harvested by trypsinization and centrifugation.  
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Immunoblot analysis: Cells were lysed in Lysis Buffer (50 mM Tris pH 7.4, 150 
mM NaCl, 0.5% NP-40) supplemented with 1 mM DTT and Protease Inhibitor Cocktail 
Set V (Sigma-Aldrich) and cleared by centrifugation. For immunoblot analysis, 4 µg 
cleared lysate (as measured by Pierce 660nm protein assay (Thermo Scientific)) were 
loaded on a 4-12% Tris-Glycine gel (Bio-Rad) then transferred onto nitrocellulose 
membranes using the Trans-Blot Turbo system according to manufacturers instructions. 
Membranes were blocked with Odyssey blocking buffer (LI-COR) and stained with 
indicated antibodies. Blots were scanned using the Odyssey imaging system (LI-COR) 
and quantified with ImageJ software. Substrate bands were normalized to Actin and/or 
vector control as indicated. For SH2-GFP-tail integrated transfections, cells were first 
sorted on a BD FACSARIA Fusion flow cytometer. 100,000 mCherry-positive (as 
indicated in figures) cells were collected and immunoblotted as above. 
 
Flow cytometry: Transfected cells were washed in ice-cold D-PBS (Gibco) and 
trypsinized then neutralized with D-MEM with no phenol red (Gibco) supplemented with 
10% FBS (Gibco). Cells were analyzed on a BD Fortessa with 10,000 cells typically 
represented. Data analysis was performed with FlowJo v10. 
  
 53 
Appendix A: Testing model substrate configuration 
When we initially set up the in vitro experiments, we wanted to test several 
domain configurations of the model substrate. The Abl SH2 domain is stable when 
purified on its own137, but is located between two folded domains in the full-length 
endogenous protein. Adding a GFP domain could change the stability of the SH2 
depending on which terminus it was put. Further, in order to ensure that degradation 
could occur, we needed to add an initiation region for the proteasome to engage177. The 
location of the 35 amino acid tail could drastically affect the degradation of the model 
protein. Therefore, we created and assayed four configurations of the model substrate 
(Figure A1a): SH2-GFP-tail (SG35), tail-GFP-SH2 (35GS), tail-SH2-GFP (35SG), and 
GFP-SH2-tail (GS35). In all cases, there was a GGSGGT linker between the SH2 and 
GFP domains and an HA tag on the opposite terminus from the tail. 
Surprisingly, we found that only two configurations degraded at all: SG35 and 
35GS (Figure A1b, c). 35GS degraded about half as well as SG35. Clearly, only when the 
initiation region was attached to the GFP domain was any degradation seen. The most 
degradation occurred when the initiation region was at the C-terminus. This is in 
agreement with findings from others in our lab, who showed that this particular sequence 
serves as a better initiation region when at the C-terminus of the folded domain 
(unpublished observations).  
We next investigated why only two of the conformations worked in our assay and 
came up with several hypotheses. First, the positioning of the substrate on the proteasome 
may not be optimal in the case of the non-degraded substrates. We showed previously 
that the geometry of the ternary complex is important, as changing the configuration of 
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Figure A1: Degradation of different model substrate geometries. 
A) Schematic of model substrate configurations. Pink circle represents SH2 domain, 
green square represents GFP, and black line represents 35 amino acid initiation region. B-
E) Fluorescence assay monitoring substrate through GFP fluorescence over time. 20 nM 
indicated substrate was incubated with 160nM of different adaptor configurations in the 
presence or absence of 25nM proteasome. Positive control: UBL-GFP-90aa tail. 
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the adaptor affected degradation ability (Figure 6). Changing the substrate configuration 
would also change the position of the substrate on the proteasome. In the case of the two 
configurations that remained stable in our assay, the adaptor, bound to the SH2 domain, 
would be very close to the initiation region and may sterically hinder the translocation201. 
We reasoned that perhaps a longer linker between the adaptor domains would help 
position the substrate correctly. However, none of the adaptors were able to induce 
degradation of those two substrates (Figure A1d, e).  
It is also possible that the substrate was getting only partially degraded. In our 
plate reader assays, we are not directly measuring the concentration of the SH2 domain, 
but rather the fluorescence of the GFP domain. If the proteasome got “stuck” after the 
SH2 domain, the GFP signal would remain stable. While the proteasome generally 
degrades processively, there are examples of partial degradation in cells when the 
proteasome encounters a stable folded domain201. For example, the structure of the 
enzyme dihydrofolate reductase (DHFR) is greatly stabilized when the ligand 
methotrexate is bound. In the presence of methotrexate, the proteasome will pause 
degradation when it encounters a DHFR domain, no matter where in the substrate the 
domain is put201. To test whether this was the case, we took the plate reader samples at 
the end of the experiment and ran them on an SDS-PAGE gel then analyzed the 
fluorescence using a Typhoon imager (Figure A2). There was no fragment with our best 
model substrate, SG35 (Figure A2a). We saw a lower molecular weight species appear at 
the end of the assay for two of the substrates, 35GS and GS35 Figure A2b and d, 
respectively). The full-length substrates were 48 kDa (GFP = 27kDa, SH2 = 17kDa, 35 
aa tail = 4.4kDa) and the fragments were ~30kDa. We were surprised to see the fragment 
in 35GS, because it degraded about 40% in our assay. If the proteasome degraded the 
GFP portion of that substrate, it would not have appeared on the Typhoon assay. It’s 
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possible that there was non-specific cleavage between the domains. The appearance of 
the ~30kDa fragment in the GS35 sample suggested that the proteasome did degrade the 
SH2 domain but could not degrade the GFP domain. In the case of 35SG, there was a 
fragment even without the proteasome (Figure A3c). This suggested that the substrate 
may be prone to proteolytic cleavage between the domains. Indeed, 35SG was less stable 
during purification, with some precipitation observed, further suggesting it is sensitive to 
proteases. 
Finally, we hypothesized that the 35aa tail was not long enough to reach the 
translocation channel. As mentioned before, the positioning of the substrate on the 
proteasome is very important, and while lengthening the adaptor did not induce 
degradation, we reasoned that perhaps lengthening the initiation region would help177. 
We therefore replaced the 35aa IR with a 90aa tail (derived from the N-terminus of 
cytochrome b2)177. This helped slightly, as about 20% of the substrate was degraded 
(Figure A3). 
While we were not able to pinpoint the exact cause of substrate stability when the 
initiation region was attached to the SH2 domain, it is reasonable to assume that a 
combination of the three hypotheses is responsible. When the SH2 domain is next to the 
initiation region, the adaptor may not be able to position the substrate so that the tail is 
accessible to the proteasome. Also, the adaptor binds to the SH2 domain with low 
nanomolar affinity137 and may stabilize the domain structure to the extent that the 
proteasome cannot degrade it. Increasing the length of the initiation region did help 
somewhat, suggesting that an extended tail allows the proteasome to engage the substrate. 
The appearance of a low molecular weight band at the end of the assay also suggests 
some intrinsic substrate instability or susceptibility to protease cleavage. 
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Figure A2: Fluorescence imaging of assay endpoints. 
A-D) Fluorescence images from Typhoon taken with a 488nm excitation filter. Indicated 
substrates (20nM) were incubated with different configurations of adaptor (160nM) with 
or without the proteasome (25nM). 
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Figure A3: Lengthening the initiation region slightly increases degradation. 
Fluorescence assay measuring the fraction of GFP signal remaining over time. 20nM 
substrate with 90aa tail was incubated with 160nM of different adaptor configurations 
and 25nM proteasome. Positive control: UBL-GFP-90aa tail. 
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Appendix B: Flow cytometry on endogenous Shp2 
After confirming that our technology is capable of degrading different model 
substrates both in vitro and in cells, the next step was to test the system on endogenous 
proteins. I chose Shp2 because it is ubiquitously expressed in the cell and readily 
detectable with an antibody (see Figure 11). To analyze cellular protein concentration, 
Western blots are widely used because they are simple to perform and show a visual of 
the protein separated on a gel. Results can be normalized and quantified by including a 
reference protein, such as actin, whose concentration is fairly consistent between cells 
that have undergone the same treatment. Western blots require two antibodies, a primary 
that recognizes the protein of interest and a secondary that recognizes the primary species 
and is conjugated to a dye or fluorophore that can be used to visualize the protein. With 
the recent advent of fluorescence or infrared labeling, Western blot quantitation has 
become more reliable than the enzymatic chemiluminescent reaction202. However, 
quantification of protein bands still relies on pixel counting in an image, which can 
become saturated and skew the results. Also, using a housekeeping gene as a loading 
reference is not reliable between cell lines and differing treatment regimens203. Therefore, 
I wanted to use an orthogonal technique to the Western blotting to quantify the depletion 
of endogenous Shp2 in cells. 
Immunofluorescence staining followed by flow cytometry is a method for 
detecting either surface or intracellular proteins204. After cells are collected, they are fixed 
and permeabilized, then stained with primary antibody followed by fluorophore-
conjugated secondary. The stained cells are then analyzed by flow cytometry (see 
Chapter 4, Methods). Using this protocol measures the secondary antibody directly 
within the cell and can be normalized to background fluorescence. Fixing the cells 
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prevents protease action that can occur in lysate during sample preparation for Western 
blots.  
I first validated the Shp2 antibody (mouse anti-Shp2, BD Biosciences) by 
transfecting the cells with siRNA (Dharmacon) and staining with a secondary conjugated 
to AlexaFluor-488 (goat anti-mouse, GE Life Sciences). Untreated cells showed an 
increase in 488 fluorescence as compared to cells without primary, and siRNA-treated 
cells had a decreased fluorescence (Figure B1a). This was confirmed by Western blot as 
well (Figure B1b). 
After antibody validation, I transfected cells with either SH2N-binding or non-
binding adaptor and performed the assay. There was a decrease in cell fluorescence in 
transfected (mCherry positive) cells containing the binding adaptor as compared to non-
binding (Figure B2a). The primary antibody was raised against the N-terminus of Shp2 
(where the SH2 domains are), and it was possible that the antibody bound Shp2 in the 
same region as the adaptor. Because the cells were fixed (and crosslinked), any 
interactions between the adaptor and Shp2 would remain intact during the assay. This is 
as opposed to Western blotting, where all interactions are destroyed upon denaturation. It 
was therefore plausible that the decrease in fluorescence was due to the antibody’s 
inability to bind to Shp2, rather than adaptor-mediated Shp2 depletion. As a control, I 
transfected the cells with monobody only (no UBL) so the Shp2 would not be targeted to 
the proteasome. Indeed, the cells showed nearly the same decrease in fluorescence with 
monobody only as compared to adaptor (Figure B2b). I concluded that the antibody and 
monobody did bind to the same place and the effect was actually from competition of 
binding rather than degradation. I saw the same effect with the SH2C-binding adaptor 
(data not shown). I also tested an antibody that bound to the Shp2 phosphatase domain 
but was unable to validate the antibody specificity with siRNA (data not shown). In the 
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end, I used Western blot only to show depletion of endogenous Shp2 and saw ~50% 
degradation (Figure 11). 
To ensure that the adaptor-induced degradation of Shp2 was proteasome-
dependent, I performed the flow cytometry assay in the presence of proteasome inhibitor 
(100 nM PS341 (bortezomib)). 24h after transfecting the cells with adaptor, I added the 
proteasome inhibitor and harvested the cells 24h later; however, I did not see any 
increase in Shp2 fluorescence (which would indicate stabilized Shp2) via flow cytometry 
(data not shown). I believe that this is due to the fact that my assay was invalid and was 
not measuring degradation, but rather antibody binding. I will perform the proteasome 
inhibition experiment on the model substrates. 
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Figure B1: Validation of anti-Shp2 antibody 
A) Histogram of cells treated with either 0.6, 1.2, or 2.4ul siRNA (20uM). Light blue 
line: cells transfected with empty pcDNA3 vector. Red line: cells stained with secondary 
antibody only (for background fluorescence). B) Western blot of cells transfected with 
empty vector or 1.2ul siRNA. 
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Figure B2: Shp2 antibody and adaptor compete for binding 
A) Histogram of transfected cells with either non-binding (blue), SH2N-binding (red) 
adaptor, or empty vector. B) Immunofluorescence of HEK293 cells transfected with 
either SH2N-binding adaptor (blue) or monobody only (red). 
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Glossary 
Abl: Abelson kinase 
ABD: Actin-binding domain 
cIAP: Cellular inhibitor of apoptosis 
Cp8: GFP circular permutant 8 
DD: Destabilizing domain 
DHFR: Dihydrofolate reductase 
DUB: Deubiquitinating enzyme 
ERAD: Endoplasmic reticulum associated degradation 
ERα: Estrogen receptor a 
HEK293: Human Embryonic Kidney 293 cells 
hHR23b: human homolog Rad23b 
IRES: Internal ribosome entry site 
MDM2: Mouse double minute 2 
miRNA: micro RNA 
PROTAC: Proteolysis targeting chimera 
RNAi: RNA interference 
SH2: Src homology domain 2 
Shp2: SH2 domain containing phosphatase 2 
siRNA: silencing RNA 
TRIM21 
UBA: Ubiquitin-associated domain 
UBL: Ubiquitin-like domain 
UPS: Ubiquitin proteasome system 
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VHL: Von Hippel Lindau 
YFP/GFP: Yellow/Green fluorescent protein 
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